Related Experiment Video
Updated: Nov 27, 2025
11:42
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
Published on: April 7, 2017
9.7K
Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma
Hironari Tamiya1,2, Hideaki Sabe1, Katsunari Yamashita1
1Department of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Case Reports in Orthopedics
|December 4, 2020
Summary
Eribulin demonstrated significant long-term effectiveness in treating advanced myxoid liposarcoma that was resistant to trabectedin. This offers a new treatment option for patients with unresectable or metastatic disease.
Area of Science:
- Oncology
- Medical Case Reports
- Pharmacology
Background:
- Malignant soft tissue sarcomas, including myxoid liposarcoma, are often treated with Adriamycin-based chemotherapy.
- Trabectedin and eribulin are alternative agents for myxoid liposarcoma when Adriamycin is unavailable or ineffective.
Observation:
- A 64-year-old female with a large myxoid liposarcoma initially refused treatment.
- After tumor progression and hip disarticulation, metastatic disease developed.
- Adriamycin was contraindicated due to cardiac dysfunction.
Findings:
- Trabectedin treatment resulted in tumor progression.
- Eribulin administration led to considerable tumor control for over two years with minimal adverse effects.
- This case highlights eribulin's efficacy in trabectedin-resistant myxoid liposarcoma.
Implications:
- Eribulin represents a valuable therapeutic option for advanced, refractory myxoid liposarcoma.
- This case underscores the importance of exploring alternative chemotherapeutic agents in sarcoma treatment.
- Further research into eribulin's role in resistant soft tissue sarcomas is warranted.
